Dr. Ulrich Dauer to team up with Chief Development Officer, Dr. Inge Lues, effective May 1, 2018; Dr. Konrad Glund and Dr. Hendrik Liebers to continue […]
HALLE (SAALE), Germany, 10 April 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
PQ912 delivers positive pharmacodynamic and efficacy results in a Phase 2a study in early stage AD patients – data presented at CTAD, Boston, November 2017 PQ912 Phase […]
HALLE (SAALE), Germany, 27 March 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish […]
The Inhibition of Glutaminyl Cyclase as a New Concept for the Treatment of Alzheimer’s Disease: PQ912, the First-In-Class QC-Inhibitor in Clinical Development for AD HALLE […]
HALLE (SAALE), Germany, 27 February 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
HALLE (SAALE), Germany, 23 January 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
HALLE (SAALE), Germany, 14 December 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
HALLE (SAALE), Germany, UTRECHT, The Netherlands, 5 December 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease […]